Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06201559
Status:
COMPLETED
Last Update Posted:
2024-01-11
First Post:
2023-12-30
Brief Title:
Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open Label Balanced Randomized Two-Treatment Four-Period Two-Sequence Single Oral Dose Full Replicate Crossover Bioequivalence Study of Albendazole Tablets IP 400 mg of Biddle Sawyer Limited GSK Group Company With Albendazole Tablets 400 mg of Glaxo SmithKline Consumer Healthcare South Africa PTY Ltd in Healthy Adult Participants Under Fed Condition
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants Researchers will compare the extent and rate to which the drug is absorbed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None